Histogen Inc (HSTO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Steven J. Mento
Employees:
31
10655 SORRENTO VALLEY ROAD SUITE 200 SAN DIEGO CA 92121
(858) 376-2600

Histogen Inc. focuses on developing hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee. The company also offers Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19.

Data derived from most recent annual or quarterly report
Market Cap 93.906 Million Shares Outstanding49.95 Million Avg 30-day Volume 968.669 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue2.8667 Debt to Equity0.0 EBITDA-11.762 Million
Price to Book Value0.604 Operating Margin-272.4288 Enterprise Value-2.481 Million
Current Ratio8.964 EPS Growth0 Quick Ratio6.231
1 Yr BETA -5.7759 52-week High/Low 18.4 / 1.61 Profit Margin-262.0523
Operating Cash Flow Growth23.684 Altman Z-Score-2.7209 Free Cash Flow to Firm -13.669 Million
Earnings Report2022-11-09
View SEC Filings from HSTO instead.

View recent insider trading info

Funds Holding HSTO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HSTO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-12:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-30:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-17:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-07:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 8.01: Other Events
  • 8-K: filed on 2022-06-02:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-29:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-25:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    KISNER DANIEL L

    • Director
    1,000 2022-06-01 2

    FUHRMANN ROCHELLE

    • Director
    1,000 2022-06-01 1

    WINDHAM-BANNISTER SUSAN RICHARDS

    • Director
    1,000 2022-06-01 1

    CREAN DAVID HUGH

    • Director
    1,000 2022-06-01 2

    JACKSON JONATHAN

    • Director
    1,000 2022-06-01 2

    SATZ BRIAN

    • Director
    1,000 2022-06-01 2

    REYES JOYCE SEE REMARKS

    • Officer
    0 2022-06-01 2

    MENTO STEVEN J INTERIM PRESIDENT AND CEO

    • Officer
    • Director
    151,642 2022-02-24 3

    KNUDSON SUSAN A. EVP, CFO & CORP SECY

    • Officer
    169,800 2022-02-17 2

    LATTERICH MARTIN SVP, TECHNICAL OPERATIONS

    • Officer
    134,900 2022-02-17 2

    PASCOE RICHARD W PRESIDENT, CEO & DIRECTOR

    • Officer
    • Director
    30,000 2021-03-30 0

    NAUGHTON GAIL K SEE REMARKS

    • Officer
    0 2021-01-13 0

    DANIELS MOYA SEE REMARKS

    • Officer
    0 2021-01-13 0

    CHANG STEPHEN

    • Director
    0 2020-10-07 0

    ZHANG YIZHUO

    • Director
    0 2020-10-07 0

    SPADA ALFRED P. EVP, R&D AND CSO

    • Officer
    No longer subject to file 2020-05-22 0

    MARSHALL KEITH W EVP, COO & CFO

    • Officer
    No longer subject to file 2020-05-22 0

    SCOTT KATHLEEN D.

    • Director
    0 2019-11-18 0

    VANDERTIE MICHELLE L VICE PRESIDENT, FINANCE

    • Officer
    0 2019-08-01 0

    HALE DAVID F

    • Director
    0 2019-06-27 0

    LARUE WILLIAM R

    • Director
    0 2019-06-27 0

    KLASSEN PRESTON

    • Director
    0 2019-06-27 0

    VAN WART HAROLD

    • Director
    0 2019-06-27 0

    HAGERTY DAVID T EVP, CLINICAL DEVELOPMENT

    • Officer
    0 2019-02-07 0

    SMITH EDWARD F III SVP, REG AFFAIRS AND QA

    • Officer
    10,875 2019-02-07 0

    RIPLEY DANIEL L. SVP, BUS DEV, P&A MGMT

    • Officer
    32,431 2019-02-07 0

    SCOPA JAMES PAUL

    • Director
    0 2018-06-21 0

    CASHION CHARLES SVP, FINANCE, CFO AND SEC.

    • Officer
    0 2017-01-26 0

    MALIK SHAHZAD

    • Director
    • 10% Owner
    0 2016-06-23 0

    LACASSE LOUIS P

    • Director
    0 2015-06-11 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    HISTOGEN INC HSTO 2022-08-18 22:15:04 UTC -349.5571 351.8771 80000
    HISTOGEN INC HSTO 2022-08-18 21:45:04 UTC -349.5571 351.8771 80000
    HISTOGEN INC HSTO 2022-08-18 21:15:04 UTC -349.5571 351.8771 80000
    HISTOGEN INC HSTO 2022-08-18 20:45:04 UTC -349.5571 351.8771 80000
    HISTOGEN INC HSTO 2022-08-18 20:15:04 UTC -349.5571 351.8771 80000
    HISTOGEN INC HSTO 2022-08-18 19:45:04 UTC -349.5571 351.8771 80000
    HISTOGEN INC HSTO 2022-08-18 19:15:04 UTC -349.5571 351.8771 80000
    HISTOGEN INC HSTO 2022-08-18 18:45:04 UTC -349.5571 351.8771 80000
    HISTOGEN INC HSTO 2022-08-18 18:15:05 UTC -349.5571 351.8771 80000
    HISTOGEN INC HSTO 2022-08-18 17:45:04 UTC -349.5571 351.8771 80000
    HISTOGEN INC HSTO 2022-08-18 17:15:04 UTC -349.5571 351.8771 85000
    HISTOGEN INC HSTO 2022-08-18 16:45:04 UTC -349.5571 351.8771 80000
    HISTOGEN INC HSTO 2022-08-18 16:15:03 UTC -349.5571 351.8771 85000
    HISTOGEN INC HSTO 2022-08-18 15:45:04 UTC -349.5571 351.8771 85000
    HISTOGEN INC HSTO 2022-08-18 15:15:05 UTC -349.5571 351.8771 85000
    HISTOGEN INC HSTO 2022-08-18 14:45:04 UTC -349.5571 351.8771 100000
    HISTOGEN INC HSTO 2022-08-18 14:15:05 UTC -349.5571 351.8771 100000
    HISTOGEN INC HSTO 2022-08-18 13:45:04 UTC -353.7566 356.0766 100000
    HISTOGEN INC HSTO 2022-08-18 13:15:04 UTC -353.7566 356.0766 100000
    HISTOGEN INC HSTO 2022-08-18 12:45:05 UTC -353.7566 356.0766 100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments